DiaSorin S.p.A., headquartered in Italy, is a prominent player in the global diagnostics industry, specialising in the development and production of innovative diagnostic solutions. Founded in 1968, the company has established a strong presence in major operational regions, including Europe, North America, and Asia. With a focus on immunodiagnostics and molecular diagnostics, DiaSorin offers a range of unique products, including its LIAISON® and Simplexa™ platforms, which are renowned for their accuracy and efficiency. The company has achieved significant milestones, such as expanding its product portfolio and enhancing its technological capabilities, solidifying its market position as a leader in the field. Recognised for its commitment to quality and innovation, DiaSorin continues to advance healthcare diagnostics, making a meaningful impact on patient care worldwide.
How does Diasorin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Diasorin's score of 59 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, DiaSorin reported total carbon emissions of approximately 248,000 kg CO2e in Great Britain, with emissions distributed across Scope 1 (80,000 kg CO2e), Scope 2 (16,000 kg CO2e), and Scope 3 (151,000 kg CO2e). Globally, the company’s emissions were significantly higher, totalling about 226,256,000 kg CO2e, with Scope 1 emissions at 3,513,000 kg CO2e, Scope 2 emissions at 12,132,000 kg CO2e (market-based), and a substantial Scope 3 contribution of 226,256,000 kg CO2e. DiaSorin has set ambitious climate commitments, aiming for Net Zero emissions by 2050. In the near term, the company projects a reduction in carbon emissions to approximately 305,010 kg CO2e by 2028, representing an 18.52% decrease from current levels. These targets encompass all scopes of emissions, reflecting a comprehensive approach to sustainability. The emissions data is sourced from DiaSorin S.p.A., the parent company, and is not cascaded from any other organization. The company is actively working towards its climate goals, demonstrating a commitment to reducing its carbon footprint in alignment with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 61,753,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,489.51 | 0,000.00 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | 000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 50% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Diasorin has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
